SMMT vs KRYS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SMMT · Summit Therapeutics$9.95 ▼ 5.87%
KRYS · Krystal Biotech$308.89 ▼ 2.19%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SMMT -44.2%
- KRYS +43.7%
Head to head
| Metric | SMMT | KRYS |
|---|---|---|
| Price | $9.95 | $308.89 |
| Change today | ▼ 5.87% | ▼ 2.19% |
| Market cap | $7.96B | $9.15B |
| Return, 3 months | -21.8% | -9.6% |
| Return, year to date | -43.1% | +25.3% |
| Return, 1 year | -38.5% | +45.7% |
| P/E (TTM) | – | 42.0 |
| P/B | 14.1 | 6.4 |
| P/E percentile vs own 5y | 44th | 68th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +30.2% |
| Net profit growth (YoY) | +10.1% | -20.5% |
| Gross margin | – | 94.3% |
| Operating margin | – | 48.4% |
| Net margin | – | 47.9% |
| Return on equity | -220.0% | 17.5% |
| Analyst target vs. price | +177.1% | +27.3% |
| Analyst buy share | 62% | 100% |
| RSI (14) | 30 | 47 |
| 30-day volatility | 109.7% | 47.9% |
| Max drawdown, 1 year | -62.3% | -21.8% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- KRYS is the largest of the group by market value.
- KRYS has returned the most over the past year.
- KRYS has been the calmest stock over the last 30 days.